A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer.

Trial Profile

A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Ofranergene obadenovec (Primary)
  • Indications Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors VBL Therapeutics
  • Most Recent Events

    • 14 Aug 2017 According to an VBL Therapeutics media release, the company provided long-term survival update for some phase 1 patients being followed up to 7 years at the BIO International Convention.
    • 17 Feb 2015 Status changed from recruiting to completed, based on information in a VBL Therapeutics media release.
    • 21 Jan 2014 Planned end date changed from 1 Sep 2012 to 1 Sep 2014 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top